Evaluation of the effect of statin use on the acenocoumarol and phenprocoumon maintenance dose

Drug Metabolism and Drug Interactions

Volumn 27, Issue 4, 2012, Pages 229-234

  Van Schie, Rianne M F ^a   Verhoef, Talitha I ^a   Boejharat, Saskia B ^a   Schalekamp, Tom ^a   Wessels, Judith A M ^b   Le Cessie, Saskia ^b   Rosendaal, Frits R ^b   Van Der Meer, Felix J M ^b,c   De Boer, Anthonius ^d   Maitland Van Der Zee, Anke Hilse ^a,d  

^a UTRECHT UNIVERSITY   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Medical diagnostic Laboratories   (Netherlands)

^d UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Coumarin; Drug drug interaction; Statin

Indexed keywords

ACENOCOUMAROL; ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PHENPROCOUMON; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; GENOTYPE; HUMAN; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; STATISTICAL SIGNIFICANCE;

ACENOCOUMAROL; ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; DRUG INTERACTIONS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PHENPROCOUMON;

EID: 84878003354     PISSN: 07925077     EISSN: None     Source Type: Journal    
DOI: 10.1515/dmdi-2012-0024     Document Type: Article

References (21)

1. GIPdatabank. Available at: http://www.gipdatabank.nl/index. asp? scherm=homepage&infoType=a. Accessed 2 April, 2012.
2. Ufer M. Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol. Clin Pharmacokinet 2005;44:1227-46.
3. Mondillo S, Ballo P, Galderisi M. Rosuvastatin-Acenocoumarol interaction. Clin Ther 2005;27:782-4.
4. Grau E, Perella M, Pastor E. Simvastatin-oral anticoagulant interaction. Lancet 1996;347:405-6.
5. Andrus MR. Oral anticoagulant drug interactions with statins: case report of fluvastatin and review of the literature. Pharmacotherapy 2004;24:285-90.
6. Westergren T, Johansson P, Molden E. Probable warfarinsimvastatin interaction. Ann Pharmacother 2007;41:1292-5.
7. Kline SS, Harrell CC. Potential warfarin-fluvastatin interaction. Ann Pharmacother 1997;31:790.
8. Trilli LE, Kelley CL, Aspinall SL, Kroner BA. Potential interaction between warfarin and fluvastatin. Ann Pharmacother 1996;30:1399-402.
9. Simonson SG, Martin PD, Mitchell PD, Lasseter K, Gibson G, Schneck DW. Effect of rosuvastatin on warfarin pharmacodynamics and pharmacokinetics. J Clin Pharmacol 2005;45:927-34.
10. Hickmott H, Wynne H, Kamali F. The effect of simvastatin co-medication on warfarin anticoagulation response and dose requirements. Thromb Haemost 2003;89:949-50.
11. Sconce EA, Khan TI, Daly AK, Wynne HA, Kamali F. The impact of simvastatin on warfarin disposition and dose requirements. J Thromb Haemost 2006;4:1422-4.
12. Lin JC, Ito MK, Stolley SN, Morreale AP, Marcus DB. The effect of converting from pravastatin to simvastatin on the pharmacodynamics of warfarin. J Clin Pharmacol 1999;39:86-90.
13. Coumarin interactions. 2011. Available at: http://www.fnt.nl/media/docs/ cumarine/cumarine-interacties-28nov-2011.pdf. Accessed on 2 April 2012.
14. van Schie RM, Wessels JA, le Cessie S, de Boer A, Schalekamp T, van der Meer FJ, et al. Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data. Eur Heart J 2011;32:1909-17.
15. Lennernas H. Clinical pharmacokinetics of atorvastatin. Clin Pharmacokinet 2003;42:1141-60.
16. Sands CD, Chan ES, Welty TE. Revisiting the significance of warfarin protein-binding displacement interactions. Ann Pharmacother 2002;36:1642-4.
17. White CM. A review of the pharmacologic and pharmacokinetic aspects of rosuvastatin. J Clin Pharmacol 2002;42:963-70.
18. Hatanaka T. Clinical pharmacokinetics of pravastatin: mechanisms of pharmacokinetic events. Clin Pharmacokinet 2000;39:397-412.
19. Wang RW, Kari PH, Lu AY, Thomas PE, Guengerich FP, Vyas KP. Biotransformation of lovastatin. IV. Identification of cytochrome P450 3A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes. Arch Biochem Biophys 1991;290:355-61.
20. Prueksaritanont T, Gorham LM, Ma B, Liu L, Yu X, Zhao JJ, et al. In vitro metabolism of simvastatin in humans [SBT]identification of metabolizing enzymes and effect of the drug on hepatic P450s. Drug Metab Dispos 1997;25:1191-9.
21. Schalekamp T, Smit C, van Geest-Daalderop JH, de Vries-Goldschmeding H, de Boer A. Discrepancies between medication records of anticoagulation clinics and pharmacy records. Pharmacoepidemiol Drug Saf 2006;15: 823-8.